Forsta AP Fonden cut its stake in shares of Stryker Co. (NYSE:SYK – Get Rating) by 25.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 57,053 shares of the medical technology company’s stock after selling 19,900 shares during the period. Forsta AP Fonden’s holdings in Stryker were worth $15,253,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. CWM LLC acquired a new position in Stryker during the 4th quarter worth approximately $1,756,000. Centaurus Financial Inc. lifted its position in Stryker by 21.4% during the 4th quarter. Centaurus Financial Inc. now owns 545 shares of the medical technology company’s stock worth $146,000 after acquiring an additional 96 shares in the last quarter. Valmark Advisers Inc. lifted its position in Stryker by 57.8% during the 4th quarter. Valmark Advisers Inc. now owns 1,913 shares of the medical technology company’s stock worth $512,000 after acquiring an additional 701 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in Stryker by 9.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 22,905 shares of the medical technology company’s stock worth $6,126,000 after acquiring an additional 2,015 shares in the last quarter. Finally, Sigma Planning Corp lifted its position in Stryker by 1.8% during the 4th quarter. Sigma Planning Corp now owns 8,483 shares of the medical technology company’s stock worth $2,269,000 after acquiring an additional 152 shares in the last quarter. 74.52% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
SYK has been the topic of a number of recent analyst reports. Citigroup cut their target price on Stryker from $310.00 to $280.00 in a research report on Tuesday, May 17th. Morgan Stanley cut their target price on Stryker from $270.00 to $220.00 and set an “equal weight” rating on the stock in a research report on Friday, July 15th. BTIG Research cut their target price on Stryker from $278.00 to $244.00 and set a “buy” rating on the stock in a research report on Monday, July 18th. Cowen cut their target price on Stryker from $305.00 to $233.00 and set an “outperform” rating on the stock in a research report on Friday, July 22nd. Finally, Stifel Nicolaus cut their target price on Stryker from $285.00 to $245.00 in a research report on Monday, July 18th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $256.00.
Stryker Price Performance
Stryker (NYSE:SYK – Get Rating) last issued its quarterly earnings data on Tuesday, July 26th. The medical technology company reported $2.25 EPS for the quarter, missing analysts’ consensus estimates of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same period in the prior year, the company earned $2.25 EPS. On average, research analysts forecast that Stryker Co. will post 9.38 earnings per share for the current year.
Stryker Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be paid a dividend of $0.695 per share. The ex-dividend date of this dividend is Thursday, September 29th. This represents a $2.78 dividend on an annualized basis and a yield of 1.29%. Stryker’s payout ratio is currently 51.20%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.
- Get a free copy of the StockNews.com research report on Stryker (SYK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.